CD19/CD20 Dual-Target in vivo CAR-T Lentiviral product
LB2409-0001
Phase 1 mab active
Quick answer
CD19/CD20 Dual-Target in vivo CAR-T Lentiviral product for Relapsed/Refractory B-cell Malignancies is a Phase 1 program (mab) at Legend Biotech Corp with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Legend Biotech Corp
- Indication
- Relapsed/Refractory B-cell Malignancies
- Phase
- Phase 1
- Modality
- mab
- Status
- active